Human Genome Sciences (HGSI) traded to the upside for the majority of Tuesday's session, but was range-bound during the final 2 hours of the afternoon. The stock closed higher by $2.79 at $28.07 on above average volume.
Human Genome Sciences and GlaxoSmithKline PLC (GSK) announced Monday morning that BENLYSTA met the primary endpoint in the second of two Phase 3 trials in seropositive patients with systemic lupus erythematosus. Human Genome Sciences closed Tuesday at its second consecutive new high for the year.
For comments and feedback: editorial@rttnews.com